Effective Pharmacologic Management of Alzheimer's Disease

American Journal of Medicine

Volumn 120, Issue 5, 2007, Pages 388-397

  Farlow, Martin R ^a   Cummings, Jeffrey L ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Donepezil; Galantamine; Management; Memantine; Pharmacotherapy; Rivastigmine

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CHOLINESTERASE INHIBITOR; CITICOLINE; CYANOCOBALAMIN; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; LEVACECARNINE; MELATONIN; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLCHOLINE; PYRIDOXINE; RAZADYNE ER; RIVASTIGMINE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALGORITHM; ALZHEIMER DISEASE; ANOREXIA; ASTHENIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DETERIORATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FALLING; FATIGUE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOCIAL INTERACTION; SOMNOLENCE; SYMPTOMATOLOGY; SYNCOPE; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

AGING; ALGORITHMS; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME;

EID: 34247232644     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.08.036     Document Type: Review

References (78)

1. Geldmacher D.S. Long-term cholinesterase inhibitor therapy for Alzheimer's disease: practical considerations for the primary care physician. Prim Care Companion J Clin Psychiatry 5 (2003) 251-259
2. Small G.W., Rabins P.V., Barry P.P., et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 278 (1997) 1363-1371
3. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 154 5 Suppl (1997) 1-39
4. Doody R.S., Stevens J.C., Beck R.N., et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 (2001) 1154-1166
5. Cummings J.L., Frank J.C., Cherry D., et al. Guidelines for managing Alzheimer's disease: part II. Treatment. Am Fam Physician 65 (2002) 2525-2534
6. Cummings J.L., Frank J.C., Cherry D., et al. Guidelines for managing Alzheimer's disease: part I. Assessment. Am Fam Physician 65 (2002) 2263-2272
7. Alzheimer's disease: risk stratification, patient evaluation, and outcome-effective pharmacologic therapy-year 2004 clinical update. Available at: http://www.ahcpub.com. Accessed June 9, 2005.
8. Doody R.S., Geldmacher D.S., Gordon B., Perdomo C.A., and Pratt R.D. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58 (2001) 427-433
9. Farlow M.R., Anand R., Messina Jr. J., Hartman R., and Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 44 (2000) 236-241
10. Raskind M.A., Peskind E.R., Wessel T., and Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54 (2000) 2261-2268
11. Raskind M.A., Peskind E.R., Truyen L., Kershaw P., and Damaraju C.V. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 61 (2004) 252-256
12. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Association, Washington, DC
13. Francis P.T., Palmer A.M., Snape M., and Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66 (1999) 137-147
14. Lemiere J., Van Gool D., and Dom R. Treatment of Alzheimer's disease: an evaluation of the cholinergic approach. Acta Neurol Belg 99 (1999) 96-106
15. Mesulam M., Guillozet A., Shaw P., and Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 9 (2002) 88-93
16. Ballard C.G. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 47 (2002) 64-70
17. Hynd M.R., Scott H.L., and Dodd P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45 (2004) 583-595
18. Farlow M.R. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. Geriatrics 59 (2004) 22-27
19. Corey-Bloom J., Anand R., and Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Psychopharmacol 2 (1998) 55-65
20. Rosler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318 (1999) 633-638
21. Tariot P.N., Solomon P.R., Morris J.C., Kershaw P., Lilienfeld S., and Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54 (2000) 2269-2276
22. Wilcock G.K., Lilienfeld S., and Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 321 (2000) 1-7
23. Rogers S.L., Farlow M.R., Doody R.S., Mohs R., and Friedhoff L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50 (1998) 136-145
24. Burns A., Rossor M., Hecker J., et al. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement Geriatr Cogn Disord 10 (1999) 237-244
25. Mohs R.C., Doody R.S., Morris J.C., et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57 (2001) 481-488
26. Winblad B., Engedal K., Soininen H., et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57 (2001) 489-495
27. Cummings J.L., Schneider L., Tariot P.N., Kershaw P.R., and Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 161 (2004) 532-538
28. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., and Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57 (2001) 613-620
29. Cummings J.L., Anand R., Koumaras B., and Hartman R. Behavioral benefits in Alzheimer's disease patients residing in a nursing home following 52 weeks of rivastigmine treatment. American Psychiatric Association 2000 Annual Meeting: The Doctor-Patient Relationship: New Research Abstracts (2000) 212-213
30. Marin D., Amaya K., Casciano R., et al. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease. Int Psychogeriatr 15 (2003) 385-398
31. Wimo A., Winblad B., Shah S.N., Chin W., Zhang R., and McRae T. Impact of donepezil treatment for Alzheimer's disease on caregiver time. Curr Med Res Opin 20 (2004) 1221-1225
32. Lopez O.L., Becker S., Wisniewski S., Saxton J., Kaufer D.I., and DeKosky S.T. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 72 (2002) 310-314
33. Geldmacher D.S., Provenzano G., McRae T., Mastey V., and Ieni J.R. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 51 (2003) 937-944
34. Wimo A., Winblad B., Engedal K., et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 15 (2003) 44-54
35. Auriacombe S., Pere J.-J., Loria-Kanza Y., and Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 18 (2002) 129-138
36. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348 (2003) 1333-1341
37. Forest Laboratories. Namenda [package insert]. St. Louis, MO, 2003.
38. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H.J. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 63 (2006) 49-54
39. Tariot P., Cummings J.L., Katz I.R., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 49 (2001) 1590-1599
40. Feldman H., Gauthier S., Hecker J., et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 51 (2003) 737-744
41. Burns A., Spiegel R., and Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 19 (2004) 243-249
42. Cummings J.L., Koumaras B., Chen M., and Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 3 (2005) 137-148
43. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 (2004) 317-324
44. Eisai Inc. Aricept [package insert]. Teaneck, NJ, 2000.
45. Novartis Pharmaceuticals Corp. Exelon [package insert]. East Hanover, NJ, 2001.
46. Ortho-McNeil Neurologics Inc. Razadyne [package insert]. Titusville, NJ, 2005.
47. Ortho-McNeil Neurologics Inc. Razadyne ER [package insert]. Titusville, NJ, 2005.
48. Defilippi J.L., and Crismon M.L. Drug interactions with cholinesterase inhibitors. Drugs Aging 20 (2003) 437-444
49. Grossberg G.T., Stahelin H.B., Messina J.C., Anand R., and Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 15 (2000) 242-247
50. Kaduszkiewicz H., Zimmermann T., Beck-Bornholdt H.P., and van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 331 (2005) 321-327
51. Petersen R.C., Thomas R.G., Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 (2005) 2379-2388
52. Salloway S., Ferris S., Kluger A., et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 63 (2004) 651-657
53. Loy C., and Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev (2006) CD001747
54. Press release: NICE consults on revised first draft guidance on the use of drugs to treat Alzheimer's disease (including a review of existing guidance no. 19). Available at: http://www.nice.org.uk/page.aspx?o=289014. Accessed June 8, 2006.
55. Diamond B., Johnson S., Torsney K., et al. Complementary and alternative medicines in the treatment of dementia: an evidence-based review. Drugs Aging 20 (2003) 981-998
56. Sierpina V.S., Sierpina M., Loera J.A., and Grumbles L. Complementary and integrative approaches to dementia. South Med J 98 (2005) 636-645
57. Birks J., Grimley E.V., and Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (2002) CD003120
58. Schneider L.S., DeKosky S.T., Farlow M.R., Tariot P.N., Hoerr R., and Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2 (2005) 541-551
59. Fioravanti M., and Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev (2005) CD000269
60. Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336 (1997) 1216-1222
61. Boothby L.A., and Doering P.L. Vitamin C and vitamin E for Alzheimer's disease. Ann Pharmacother 39 (2005) 2073-2080
62. Henderson V.W. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 138 (2006) 1031-1039
63. Almeida O.P., and Flicker L. Association between hormone replacement therapy and dementia: is it time to forget?. Int Psychogeriatr 17 (2005) 155-164
64. Reines S.A., Block G.A., Morris J.C., et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62 (2004) 66-71
65. Thal L.J., Ferris S.H., Kirby L., et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30 (2005) 1204-1215
66. Higgins J.P., and Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev (2003) CD001015
67. Hudson S., and Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev (2003) CD003158
68. Jansen S.L., Forbes D.A., Duncan V., and Morgan D.G. Melatonin for cognitive impairment. Cochrane Database Syst Rev (2006) CD003802
69. Malouf R., and Areosa Sastre A. Vitamin B12 for cognition. Cochrane Database Syst Rev (2003) CD004326
70. Malouf R., and Grimley Evans J. The effect of vitamin B6 on cognition. Cochrane Database Syst Rev (2003) CD004393
71. Areosa S.A., McShane R., and Sherriff F. Memantine for dementia. Cochrane Database Syst Rev (2004) CD003154
72. Folstein M.F., Folstein S.E., and McHugh P.R. ″Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 12 (1975) 189-198
73. Lawton M.P., and Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9 (1969) 179-186
74. Morris J.C., Edland S., Clark C., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 43 (1993) 2457-2465
75. Schneider L.S., Olin J.T., Doody R.S., et al. Validity and reliability of the Alzheimer's disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 11 Suppl 2 (1997) S22-S32
76. Pfeffer R.I., Kurosaki T.T., Harrah Jr. C.H., Chance J.M., and Filos S. Measurement of functional activities in older adults in the community. J Gerontol 37 (1982) 323-329
77. Kaufer D.I., Cummings J.L., Ketchel P., et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12 (2000) 233-239
78. Gauthier S., Emre M., Farlow M.R., Bullock R., Grossberg G.T., and Potkin S.G. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin 19 (2003) 707-714